Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464976 | 1.00 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Hydrochloric Acid SCHEMBL30389813 | 0.98 | ALDH1A1 (0.57) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL767075 | 0.89 | ALDH1A1 (0.53) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL29452971 | 0.77 | ALDH1A1 (0.63) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL5748057 | 0.76 | ALDH1A1 (0.61) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL11486223 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL7663294 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL375956 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL5170029 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL2009847 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238139-B1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-09-27 | — | — | EP | claimed |
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | BARRE LOUISA | 2010-11-18 | — | — | US | claimed |
| EP-2238139-A2 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2010-10-13 | — | — | EP | claimed |
| WO-2009087066-A2 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-07-16 | — | — | WO | claimed |
| EP-0706387-B1 | NEW PROCEDURE TO BLOCK THE REPLICATION OF REVERSE TRANSCRIPTASE DEPENDENT VIRUSES BY THE USE OF INHIBITORS OF DEOXYNUCLEOTIDES SYNTHESIS | US GOV HEALTH & HUMAN SERV (US) | 2004-08-18 | — | — | EP | claimed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | claimed |
| US-5856085-A | INCUBATION SINGLE-STRANDED NUCLEIC ACIDS; AMPLIFICATION; ANALYZING | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-01-05 | — | — | US | claimed |
| EP-0614462-B1 | NEW METHOD OF PREPARING 2-FLUOROPURINE DERIVATIVES | SCHERING AG (DE) | 1997-12-29 | — | — | EP | claimed |
| US-5696255-A | Process for the production of 2-fluoropurine derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | claimed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | claimed |
| WO-1997020072-A1 | COMPOSITIONS AND METHODS OF DEVELOPING OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE ANALOGS HAVING ANTIVIRAL ACTIVITY | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-06-05 | — | — | WO | claimed |
| EP-4612294-A2 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4399217-A2 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4399301-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118354672-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-0614462-A1 | NEW METHOD OF PREPARING 2-FLUOROPURINE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-09-14 | — | — | EP | disclosed |
| US-5336764-A | 2'-fluorofuranosyl derivatives and novel method of preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-08-09 | — | — | US | disclosed |
| US-5336764-A | 2'-fluorofuranosyl derivatives and novel method of preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-08-09 | — | — | US | disclosed |
| WO-1993011144-A1 | NEW METHOD OF PREPARING 2-FLUOROPURINE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-06-10 | — | — | WO | disclosed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | TPMT, NUDT1, DUT | ALDH1A1 341/4885KDM4E 884/4885CDK2 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.